Abstract

Background: Lamotrigine (LTG) is commonly used for treatment of epilepsy and bipolar disorder. It is one of the common cause of cutaneous adverse drug reactions (CADR). Clinical symptoms of LTG-induced CADR range from maculopapular exanthema (MPE) to severe cutaneous adverse reactions (SCAR). This study aimed to determine the association of the LTG-induced CADR with human leukocyte antigen (HLA) alleles in Thai patients.Methods: Fifteen patients with LTG-induced CADR [10 MPE; 4 Stevens–Johnson syndrome; and 1 drug reaction with eosinophilia and systemic symptoms] and 50 LTG-tolerant controls were included in the study. HLA-A and HLA-B genotyping was performed using polymerase chain reaction-sequence-specific oligonucleotides probes.Results: The proportion of HLA-A∗02:07 and HLA-B∗15:02 allele carriers were significantly higher in the LTG-induced CADR group than in the tolerant controls [odds ratio (OR): 7.83; 95% confidence interval (CI): 1.60–38.25; P = 0.013, and OR: 4.89; 95% CI: 1.28–18.67; P = 0.014]. In addition, subjects with HLA-A∗33:03, HLA-B∗15:02, and HLA-B∗44:03 were significantly higher in the LTG-induced MPE group than in the tolerant controls (OR: 8.27; 95% CI: 1.83–37.41; P = 0.005, OR: 7.33; 95% CI: 1.63–33.02; P = 0.005; and OR: 10.29; 95% CI: 1.45–72.81; P = 0.029). In contrast to the LTG-induced MPE group, there were no significant differences between HLA alleles and LTG-induced SCAR group.Conclusion: HLA-A∗02:07 and HLA-B∗15:02 were associated with LTG-induced CADR in Thai patients. We also identified an association between HLA-A∗33:03, HLA-B∗15:02, and HLA-B∗44:03 and LTG-induced MPE in this population. These results suggest that these alleles could be useful screening markers for preventing CADR before LTG treatment in Thai patients, but further replication studies with larger sample sizes are needed.

Highlights

  • MATERIALS AND METHODSLamotrigine (LTG) is a phenyltriazine derivative which is used in the treatment of epilepsy and bipolar disorder

  • The proportion of patients carrying the human leukocyte antigen (HLA)-B∗15:02 allele was significantly higher in LTGinduced cutaneous adverse reactions (CADR) cases than in both the treatment controls and general population groups with odds ratios (OR) of 4.89, 95% CI = 1.28–18.66, P-value = 0.014 and OR = 3.63, 95% CI = 1.27– 10.34, P-value = 0.027, respectively

  • We found a significant association between LTG-induced CADR patients and both HLA-B∗35:08 and HLA-B∗39:01 when compared with the general population with OR = 70.36, 95% CI = 4.19– 1182.21, P-value = 0.030 and OR = 10.68, 95% CI = 2.20–51.83, P-value = 0.022, respectively

Read more

Summary

Introduction

Lamotrigine (LTG) is a phenyltriazine derivative which is used in the treatment of epilepsy and bipolar disorder. It is one of the aromatic antiepileptic drugs (AEDs) which together are the most common cause of cutaneous adverse reactions (CADR) (Arif et al, 2007). CADR manifestations range from mild maculopapular exanthema (MPE) to severe cutaneous adverse reactions (SCAR), including Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reactions with eosinophilia and systemic symptoms (DRESS). Lamotrigine (LTG) is commonly used for treatment of epilepsy and bipolar disorder It is one of the common cause of cutaneous adverse drug reactions (CADR). Clinical symptoms of LTG-induced CADR range from maculopapular exanthema (MPE) to severe cutaneous adverse reactions (SCAR). This study aimed to determine the association of the LTG-induced CADR with human leukocyte antigen (HLA) alleles in Thai patients

Objectives
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call